Probiotics might offer an alternative or adjuvant approach to conventional therapy of ulcerative colitis (UC) by altering the intestinal microflora and modulating the host immune system. At Creative Biolabs, we offer one-stop solutions for probiotic drug development and characterization to promote the identification of probiotic drugs to meet your specific project demands.
Introduction of UC
UC is a chronic inflammatory bowel disease of unknown etiology that is characterized by diffuse mucosal inflammation of the colon and acute exacerbations followed by remissions. Patients usually present with debilitating symptoms such as bloody diarrhoea, abdominal pain, urgency, or tenesmus. The pathogenesis of UC likely involves the interplay of different factors, including the genetic factors, environment, the gut microbiota, and the immune system. Current medical management involves a variety of treatments, including aminosalicylates, corticosteroids, and immunosuppressant agents, that suppress intestinal inflammation associated with UC. However, prolonged use of chemicals may result in potential adverse events. Hence, new alternative therapeutic approaches for the treatment of UC are constantly being sought. Recently, probiotic therapy has been recognized to be safe and effective for patients with UC.
